ProPhase Labs shares surge 32.60% premarket after securing U.S. patent for esophageal adenocarcinoma risk assessment test.

ProPhase Labs Inc. (NASDAQ:PRPH) surged 32.6% in premarket trading, driven by the announcement on August 12, 2025, of full U.S. Patent Office approval for its esophageal adenocarcinoma risk assessment test. The patent strengthens the company’s intellectual property position for its BE-Smart™ diagnostic platform, which was recently validated by a successful clinical study demonstrating its effectiveness in detecting esophageal cancer. This development, coupled with prior reports of a 38% share price increase following the patent news, underscores renewed investor confidence in ProPhase’s commercialization potential and strategic focus on diagnostic innovation. Earlier financing activities, such as a $3 million convertible note issuance in July, and recent governance updates, including a new CFO appointment, further support operational stability but were less immediately impactful than the patent milestone.